EA201691420A1 - Композиции енолазы 1 (eno1) и их применение - Google Patents
Композиции енолазы 1 (eno1) и их применениеInfo
- Publication number
- EA201691420A1 EA201691420A1 EA201691420A EA201691420A EA201691420A1 EA 201691420 A1 EA201691420 A1 EA 201691420A1 EA 201691420 A EA201691420 A EA 201691420A EA 201691420 A EA201691420 A EA 201691420A EA 201691420 A1 EA201691420 A1 EA 201691420A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- subject
- eno1
- blood glucose
- enolase
- muscle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 101150015836 ENO1 gene Proteins 0.000 abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008103 glucose Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 101710165425 Alpha-enolase Proteins 0.000 abstract 2
- 102100038910 Alpha-enolase Human genes 0.000 abstract 2
- 101710184673 Enolase 1 Proteins 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926913P | 2014-01-13 | 2014-01-13 | |
| US201462009783P | 2014-06-09 | 2014-06-09 | |
| US201562100881P | 2015-01-07 | 2015-01-07 | |
| PCT/US2015/011275 WO2015106295A2 (en) | 2014-01-13 | 2015-01-13 | Enolase 1 (eno1) compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691420A1 true EA201691420A1 (ru) | 2016-12-30 |
Family
ID=53524434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691420A EA201691420A1 (ru) | 2014-01-13 | 2015-01-13 | Композиции енолазы 1 (eno1) и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10188707B2 (enExample) |
| EP (2) | EP3094341B1 (enExample) |
| JP (2) | JP6644006B2 (enExample) |
| KR (1) | KR20160106175A (enExample) |
| CN (3) | CN112336851A (enExample) |
| AU (2) | AU2015204451A1 (enExample) |
| BR (1) | BR112016016153A2 (enExample) |
| CA (2) | CA2936694A1 (enExample) |
| EA (1) | EA201691420A1 (enExample) |
| HK (1) | HK1231425A1 (enExample) |
| IL (1) | IL246720A0 (enExample) |
| MX (1) | MX2016009102A (enExample) |
| SG (1) | SG11201605698XA (enExample) |
| WO (2) | WO2015106296A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201605698XA (en) * | 2014-01-13 | 2016-08-30 | Berg Llc | Enolase 1 (eno1) compositions and uses thereof |
| CN107847560A (zh) * | 2015-06-22 | 2018-03-27 | 博格有限责任公司 | 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途 |
| WO2017062363A1 (en) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| US20200185063A1 (en) | 2016-06-05 | 2020-06-11 | Berg Llc | Systems and methods for patient stratification and identification of potential biomarkers |
| CN107991493B (zh) * | 2017-11-22 | 2020-03-31 | 中国医科大学附属第一医院 | 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用 |
| CN112111462B (zh) * | 2020-09-14 | 2022-08-23 | 兰州大学 | 烯醇化酶eno1单克隆抗体及其应用 |
| EP4436613A4 (en) * | 2021-11-26 | 2025-11-12 | Hunilife Biotechnology Inc | METHODS OF GLYCOLYSIS REGULATION BY TARGETING EXTRACELLULAR ALPHA-ENOLASE FOR THE TREATMENT OF HUMAN DISEASES |
| CN114533902A (zh) * | 2022-02-28 | 2022-05-27 | 河南师范大学 | 一种过表达lrrc15基因的质粒载体及其制备方法和应用 |
| CN115786317A (zh) * | 2022-12-12 | 2023-03-14 | 江苏三联生物工程股份有限公司 | 重组神经元特异性烯醇化酶及其制备方法与应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE244576T1 (de) | 1992-09-25 | 2003-07-15 | Neorx Corp | Therapeutischer inhibitor der vaskulären glatten muskelzellen |
| CZ122697A3 (en) | 1994-10-25 | 1997-09-17 | Immulogic Pharma Corp | Preparations and methods of treating disseminated sclerosis |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US20030044795A1 (en) | 1996-09-06 | 2003-03-06 | Inger Byrajalsen | Biochemical markers of the human endometrium |
| US7078375B1 (en) * | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
| US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| JP2003510033A (ja) | 1999-09-01 | 2003-03-18 | サブサイダリー ナンバースリー インコーポレイテッド | ヒト細胞遺伝子をダウンレギュレートすることにより、ヒト免疫不全ウイルス感染を阻止するための組成物および方法 |
| EP1226280A4 (en) | 1999-10-25 | 2003-10-15 | Univ Princeton | GENETIC SEQUENCES ASSOCIATED WITH THE PROLIFERATION AND PATHOLOGIES OF NEURONAL CELLS |
| AU781951B2 (en) | 2000-02-02 | 2005-06-23 | Transgene S.A. | Targeting peptides |
| US20030203372A1 (en) | 2000-12-08 | 2003-10-30 | Ward Neil Raymond | Analysis method |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| US20040058326A1 (en) | 2001-07-27 | 2004-03-25 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
| US20050191627A1 (en) | 2001-09-28 | 2005-09-01 | Incyte Corporation | Enzymes |
| WO2003064501A1 (en) | 2002-01-31 | 2003-08-07 | Clarke Slemon | Conformationally restricted compounds as dendrimer cores |
| US20050222023A1 (en) | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
| JP2004081111A (ja) * | 2002-08-27 | 2004-03-18 | Yamaguchi Technology Licensing Organization Ltd | 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法 |
| EP2364716A3 (en) | 2002-11-08 | 2012-01-11 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| CN100469370C (zh) * | 2002-12-06 | 2009-03-18 | 法布罗根股份有限公司 | 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用 |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| AU2003294828A1 (en) | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
| WO2004061088A2 (en) | 2002-12-30 | 2004-07-22 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2004084950A2 (en) | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
| US7473531B1 (en) | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005073621A (ja) | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
| EP1667710A2 (en) | 2003-10-03 | 2006-06-14 | VIB vzw | Means and methods for the recruitment and identification of stem cells |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| JP2006528361A (ja) | 2004-07-06 | 2006-12-14 | クンイル ファーマシューティカル カンパニー リミテッド | アルドラーゼを含む網膜血管疾患診断用組成物およびその診断方法 |
| US20090221505A1 (en) | 2004-11-16 | 2009-09-03 | Mikhail Kolonin | Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display |
| WO2006073254A1 (en) | 2005-01-03 | 2006-07-13 | Sook-Yeong Jeon | Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| US20070248628A1 (en) | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| TWI304443B (en) | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| WO2008012362A2 (en) | 2006-07-27 | 2008-01-31 | Oxford Genome Sciences (Uk) Ltd | New protein isoforms and uses thereof |
| WO2008037792A1 (en) | 2006-09-29 | 2008-04-03 | Ribovax Biotechnologies Sa | Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma |
| US20100047256A1 (en) | 2007-01-25 | 2010-02-25 | Imperial Innovations Limited | Methods |
| US20090110662A1 (en) | 2007-04-30 | 2009-04-30 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| DK2167136T3 (en) | 2007-07-12 | 2016-07-25 | Biomarin Tech Bv | Molecules for targeting compounds at different selected organs or tissues |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| JP5429707B2 (ja) | 2008-03-27 | 2014-02-26 | 国立大学法人群馬大学 | 微粒子およびその製造方法 |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| DK2315532T3 (da) | 2008-07-18 | 2014-10-20 | Hills Pet Nutrition Inc | Sammensætninger og fremgangsmåder til behandling af forstyrrelser, der er associeret med overvægtige dyr |
| EP2194382A1 (en) | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| IT1398782B1 (it) | 2009-09-11 | 2013-03-18 | Novelli | Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi. |
| WO2011064552A1 (en) | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011072290A2 (en) * | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| WO2011147981A2 (en) | 2010-05-28 | 2011-12-01 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| EP2638058B1 (en) | 2010-11-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| US20140086895A1 (en) | 2011-05-10 | 2014-03-27 | Universite De Rouen | Methods and pharmaceutical compositions for the treatment of autoimmune diseases |
| GB201113814D0 (en) | 2011-08-10 | 2011-09-28 | Proteome Sciences R & D Gmbh & Co Kg | Materials and methods for determining sensitivity potential of compounds |
| ES2876939T3 (es) | 2011-08-30 | 2021-11-15 | Res & Innovation Uk | Péptidos penetradores de células que tienen un dominio hidrófobo central |
| HUE045359T2 (hu) | 2011-12-14 | 2019-12-30 | Univ Texas | Kollaterális gén inaktiváló biomarkerek és célsejtek a rákterápiában |
| EP2877214B1 (en) | 2012-07-26 | 2019-04-24 | Joslin Diabetes Center, Inc. | Predicting diabetic complications |
| EP2914247A4 (en) | 2012-10-30 | 2016-06-29 | Particle Sciences Inc | DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING ELEMENTS |
| SG11201605698XA (en) * | 2014-01-13 | 2016-08-30 | Berg Llc | Enolase 1 (eno1) compositions and uses thereof |
| CN107847560A (zh) | 2015-06-22 | 2018-03-27 | 博格有限责任公司 | 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途 |
| EP3322405A4 (en) | 2015-07-16 | 2019-01-23 | Berg LLC | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF |
-
2015
- 2015-01-13 SG SG11201605698XA patent/SG11201605698XA/en unknown
- 2015-01-13 WO PCT/US2015/011276 patent/WO2015106296A1/en not_active Ceased
- 2015-01-13 CA CA2936694A patent/CA2936694A1/en not_active Abandoned
- 2015-01-13 US US14/596,207 patent/US10188707B2/en active Active
- 2015-01-13 US US14/596,208 patent/US10188708B2/en active Active
- 2015-01-13 CN CN202011098097.6A patent/CN112336851A/zh active Pending
- 2015-01-13 WO PCT/US2015/011275 patent/WO2015106295A2/en not_active Ceased
- 2015-01-13 AU AU2015204451A patent/AU2015204451A1/en not_active Abandoned
- 2015-01-13 AU AU2015204452A patent/AU2015204452A1/en not_active Abandoned
- 2015-01-13 CN CN201580012874.1A patent/CN106102835B/zh not_active Expired - Fee Related
- 2015-01-13 JP JP2016563908A patent/JP6644006B2/ja not_active Expired - Fee Related
- 2015-01-13 EP EP15735001.8A patent/EP3094341B1/en active Active
- 2015-01-13 KR KR1020167022300A patent/KR20160106175A/ko not_active Withdrawn
- 2015-01-13 EP EP15735142.0A patent/EP3094379A4/en not_active Withdrawn
- 2015-01-13 EA EA201691420A patent/EA201691420A1/ru unknown
- 2015-01-13 HK HK17105147.2A patent/HK1231425A1/zh unknown
- 2015-01-13 MX MX2016009102A patent/MX2016009102A/es unknown
- 2015-01-13 CA CA2936691A patent/CA2936691A1/en not_active Abandoned
- 2015-01-13 CN CN201580012892.XA patent/CN106659766B/zh active Active
- 2015-01-13 JP JP2016563909A patent/JP6629234B2/ja not_active Expired - Fee Related
- 2015-01-13 BR BR112016016153A patent/BR112016016153A2/pt not_active Application Discontinuation
-
2016
- 2016-07-11 IL IL246720A patent/IL246720A0/en unknown
-
2018
- 2018-11-28 US US16/202,989 patent/US11224641B2/en active Active
- 2018-11-28 US US16/203,016 patent/US20190307864A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| EA201792203A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
| HK1213483A1 (zh) | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 | |
| MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
| EA201590715A1 (ru) | Производные эксендина-4 как двойные агонисты glp1/глюкагона | |
| WO2015105981A3 (en) | Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment | |
| EA201492031A1 (ru) | Способы лечения диабетической ретинопатии и других офтальмологических заболеваний | |
| MX2021013880A (es) | Polimeros enlazados al proton para administracion oral. | |
| PH12019502655A1 (en) | Acylated insulin compound | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| MX357071B (es) | Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes. | |
| JOP20170040B1 (ar) | مركب لخفض جلوكوز الدم | |
| BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
| WO2014049438A3 (en) | Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof | |
| MX2017000878A (es) | Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre. | |
| WO2016126026A3 (ko) | 당뇨병 치료 조성물 및 이의 용도 | |
| MD696Y (en) | Method for treatment of diabetic foot complications | |
| Leguay | Allergic reaction: case report | |
| Ozturk | New onset diabetes mellitus post transplantation and diabetic ketoacidosis: case report | |
| RU2012110137A (ru) | Способ лечения инсулинорезистентности | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
| UA101059U (ru) | Метод аутолипографтинга при лечении ожогов | |
| WO2014014816A3 (en) | Methods of treating glucose metabolism disorders | |
| UA111116C2 (uk) | Збалансований інфузійний розчин |